These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30964695)

  • 1. Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.
    Lv P; Liu X; Chen X; Liu C; Zhang Y; Chu C; Wang J; Wang X; Chen X; Liu G
    Nano Lett; 2019 May; 19(5):2993-3001. PubMed ID: 30964695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
    Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
    Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11.
    Mato-Berciano A; Morgado S; Maliandi MV; Farrera-Sal M; Gimenez-Alejandre M; Ginestà MM; Moreno R; Torres-Manjon S; Moreno P; Arias-Badia M; Rojas LA; Capellà G; Alemany R; Cascallo M; Bazan-Peregrino M
    J Control Release; 2021 Apr; 332():517-528. PubMed ID: 33675877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
    Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
    J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosilicified oncolytic adenovirus for cancer viral gene therapy.
    Kong H; Zhao R; Zhang Q; Iqbal MZ; Lu J; Zhao Q; Luo D; Feng C; Zhang K; Liu X; Kong X
    Biomater Sci; 2020 Oct; 8(19):5317-5328. PubMed ID: 32779647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma.
    Jia X; Wang L; Feng X; Liu W; Wang X; Li F; Liu X; Yu J; Yu B; Yu X
    Nano Lett; 2023 Dec; 23(23):11120-11128. PubMed ID: 38032110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
    Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
    Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy.
    Ran L; Tan X; Li Y; Zhang H; Ma R; Ji T; Dong W; Tong T; Liu Y; Chen D; Yin X; Liang X; Tang K; Ma J; Zhang Y; Cao X; Hu Z; Qin X; Huang B
    Biomaterials; 2016 May; 89():56-66. PubMed ID: 26950165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the Antitumor Efficacy of Oncolytic Adenovirus Through Sonodynamic Therapy-Augmented Virus Replication.
    Ding J; Su R; Yang R; Xu J; Liu X; Yao T; Li S; Wang C; Zhang H; Yue Q; Zhan C; Li C; Gao X
    ACS Nano; 2024 Jul; 18(28):18282-18298. PubMed ID: 38953884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
    Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
    Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
    Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
    Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system.
    Aoyama K; Kuroda S; Morihiro T; Kanaya N; Kubota T; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Sci Rep; 2017 Oct; 7(1):14177. PubMed ID: 29074882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of oncolytic adenovirus and its application in cancer therapy.
    Liang Y; He J; Zhao Y
    Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery systems for enhancing oncolytic adenoviruses efficacy.
    Zhou YC; Zhang YN; Yang X; Wang SB; Hu PY
    Int J Pharm; 2020 Dec; 591():119971. PubMed ID: 33059014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
    Kwon OJ; Kang E; Kim S; Yun CO
    J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
    González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
    J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.